BUDX News and Press, Cannabis Growth ETF From 12/07/21

Announced acquisition of New Mexico’s 2nd largest operator. Additionally announced a $95M financing to fund transaction and other M&A opportunities. New Mexico to be a high growth state in ’22 as rec sales commence in late March at the latest. Schwazze now we...

It's an appropriate time to take stock of the developments in the cannabis industry. One year in cannabis can feel like several given the many ups and downs that take place in a 12 month span. 2021 delivered a mixed bag of wins and losses. For further details see: 2021 -...

Q3 results impacted by CA pricing but reflect execution. Urbn Leaf acquisition expands retail presence particularly in Southern CA. Loudpack enhances production capabiltiies and brand portfolio. Deals follow acquisitions of Sublime brands and cultivation assets in recent months. ...

Jon DeCourcey, formerly of Canaccord now with Viridian Capital Advisors, joins us to discuss recent cannabis earnings and why he favors mid-tier multi-state operators (MSOs) over the Big 5. SAFE Banking expectations, how he sees valuations growing. Why retail investors should be e...

GAGE growing with retail and cultivation assets in MI. TerrAscend deal poised to close in early ’22. Reduce rating to hold and price target to $1.91 reflecting TerrAscend deal. Potential for upside in short term on TerrAscend stock gains on legislative news or additiona...

Kristen Yoder, host of The CannaBS Detector and a veteran of the industry, gives an unvarnished take on the cannabis industry. Kristen's #1 complaint about the industry. Why she'd rather be short cannabis stocks than long and where she does feel comfortable putting her money. ...

Timely, edifying episode with industry expert Brady Cobb. Recent cannabis legislation; moving from optics to real reform. SAFE Banking, uplisting and what it all means for cannabis investors. MSOs, ETFs new and old, future valuations, Florida and NY/NJ markets. Selling to Cres...

Q3 results in line with estimates. 22 Target Revenue remains $800M, adjusted EBITDA guidance reduced on low end, now at $250M to $300M (was $300M). Expanding presence in IL with Dispensary 33 acquisition. Confident that additional M&A looms given management interest and ca...

Q3/21 miss on pricing pressure. Expect lower flower pricing to continue into 2022. Pricing pressure furthers our positive view on LOWLF’s differentiated initiatives put in place by management including brand acquisition, buildout of processing business and decision not to a...

Q3/21 EBITDA miss on delayed product approval in PA, MA cultivation underperformance and inflated freight costs. Expect freight costs to linger into ’22. Management reduced ’21 adjusted EBITDA guidance by nearly 20% at midpoint while stating that revenues would come ...